Parabilis CMO to depart effective Sept. 30, 2026

Parabilis Medicines, Inc. (PBLS) reports that Chief Medical Officer Fawzi Benzaghou, M.D. will transition from the company.

Rhea-AI Filing Summary

Parabilis Medicines, Inc. (PBLS) reports that Chief Medical Officer Fawzi Benzaghou, M.D. will transition from the company. The company and Dr. Benzaghou mutually agreed to his departure on August 28, 2026, with his service ending effective September 30, 2026.

In connection with this transition, Dr. Benzaghou is entitled to receive severance benefits in accordance with the terms of his existing employment agreement with Parabilis Medicines.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Agreement date: August 28, 2026 Effective departure date: September 30, 2026 Form type: Form 8-K

3 metrics

Agreement date August 28, 2026 Date Parabilis Medicines and its CMO mutually agreed to his transition

Effective departure date September 30, 2026 Effective date of Chief Medical Officer’s departure from Parabilis Medicines

Form type Form 8-K Current report filed regarding officer departure and related arrangements

Key Terms

Chief Medical Officer, severance benefits, employment agreement, emerging growth company

4 terms

Chief Medical Officer technical

"the Company’s Chief Medical Officer, mutually agreed that Dr. Benzaghou"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

severance benefits financial

"In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits"

employment agreement financial

"severance benefits pursuant to the terms of his employment agreement with the Company"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Parabilis Medicines (PBLS) announce?

Parabilis Medicines announced that its Chief Medical Officer, Fawzi Benzaghou, M.D., will transition from the company under a mutually agreed arrangement, with his departure effective September 30, 2026.

When is the Parabilis Medicines (PBLS) CMO’s departure effective?

The departure of Chief Medical Officer Fawzi Benzaghou, M.D. from Parabilis Medicines is effective as of September 30, 2026, following a mutual agreement reached on August 28, 2026.

Will the departing CMO of PBLS receive severance benefits?

Yes. Parabilis Medicines states that Dr. Fawzi Benzaghou will receive severance benefits in connection with his departure, pursuant to the terms of his employment agreement with the company.

What was the role of Fawzi Benzaghou, M.D. at Parabilis Medicines (PBLS)?

Fawzi Benzaghou, M.D. served as the Chief Medical Officer of Parabilis Medicines, Inc., a senior leadership role responsible for medical and clinical oversight at the company.

On what date did PBLS and its CMO agree to the transition?

Parabilis Medicines and Chief Medical Officer Fawzi Benzaghou, M.D. mutually agreed to his transition from the company on August 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:05 PM EDT Learn about SEC filing dates

0001657677false00016576772026-08-282026-08-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2026

Parabilis Medicines, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-43331	47-4505725
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
30 Acorn Park Drive
Cambridge, Massachusetts		02140
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 945-9510

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PBLS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Officer, mutually agreed that Dr. Benzaghou would transition from the Company effective as of September 30, 2026. In connection with his departure from the Company, Dr. Benzaghou will receive severance benefits pursuant to the terms of his employment agreement with the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

					Parabilis Medicines, Inc.
Date:		September 2, 2026	By:		/s/ Thomas Kotarakos
					Thomas Kotarakos
					Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 27.4 KB